Immunomodulating Activity of Pleurotus eryngii Mushrooms Following Their In Vitro Fermentation by Human Fecal MicrobiotaShow others and affiliations
2022 (English)In: Journal of Fungi, E-ISSN 2309-608X, Vol. 8, no 4, article id 329Article in journal (Refereed) Published
Abstract [en]
Recent studies have revealed the crucial role of several edible mushrooms and fungal compounds, mainly polysaccharides, in human health and disease. The investigation of the immunomodulating effects of mushroom polysaccharides, especially beta-glucans, and the link between their anticancer and immunomodulatory properties with their possible prebiotic activity on gut micro-organisms has been the subject of intense research over the last decade. We investigated the immunomodulating effects of Pleurotus eryngii mushrooms, selected due to their high beta-glucan content, strong lactogenic effect, and potent geno-protective properties, following in vitro fermentation by fecal inocula from healthy elderly volunteers (>60 years old). The immunomodulating properties of the fermentation supernatants (FSs) were initially investigated in U937-derived human macrophages. Gene expression as well as pro- (TNF-alpha, IL-1 beta) and anti-inflammatory cytokines (IL-10, IL-1R alpha) were assessed and correlated with the fermentation process. The presence of P. eryngii in the fermentation process led to modifications in immune response, as indicated by the altered gene expression and levels of the cytokines examined, a finding consistent for all volunteers. The FSs immunomodulating effect on the volunteers' peripheral blood mononuclear cells (PBMCs) was verified through the use of cytometry by time of flight (CyTOF) analysis.
Place, publisher, year, edition, pages
MDPI, 2022. Vol. 8, no 4, article id 329
Keywords [en]
edible mushrooms, macrophages, cytokines, PBMCs
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
URN: urn:nbn:se:oru:diva-98824DOI: 10.3390/jof8040329ISI: 000785110600001PubMedID: 35448559Scopus ID: 2-s2.0-85127725671OAI: oai:DiVA.org:oru-98824DiVA, id: diva2:1655381
Funder
European Commission
Note
Funding agency:
Greek national funds, through the Operational Program Competitiveness, Entrepreneurship and Innovation under the call RESEARCH-CREATE-INNOVATE T1EDK-03404
2022-05-022022-05-022024-08-30Bibliographically approved